Program
fludarabine
Also written as “Fludarabine”, “Cyclophosphamide,Fludarabine” and “TC-D101 CAR-T”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Non-Hodgkin · Glioblastoma, led by 18 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Biotech | 99 open or running | phase 2since Apr 5, 2026 | Mar 14, 2026 | Feb 18, 2027phase 1 · NCT07480941 |
| Hoffmann-La Roche | 60 open or running | phase 4since Jan 4, 2011 | Oct 16, 2007 | none ahead |
| Allogene Therapeutics | 32 open or running | phase 2since Dec 8, 2022 | Dec 8, 2022 | Dec 2027phase 2 · NCT06500273 |
| Hangzhou Huasai Biomedicine | 22 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | Aug 30, 2027phase 1 · NCT07105176 |
| Shanghai First Song Biotechnology | 21 open or running | early phase 1since Jul 30, 2024 | Jul 30, 2024 | none ahead |
| adicet-therapeutics | 10 open or running | phase 1since Jan 26, 2021 | Jan 26, 2021 | none ahead |
| biotech-equity-partners-pty-ltd | 10 open or running | phase 1since Feb 20, 2008 | Feb 20, 2008 | none ahead |
| Bristol-Myers Squibb | 11 open or running | phase 1since Feb 7, 2025 | Feb 7, 2025 | Mar 15, 2029phase 1 · NCT07115745 |
| Caribou Biosciences | 11 open or running | phase 1since Nov 16, 2020 | Nov 16, 2020 | none ahead |
| carsgen-therapeutics-co-ltd | 10 open or running | phase 1since Aug 9, 2016 | Aug 9, 2016 | none ahead |
| Gilead Sciences | 10 open or running | phase 1since Oct 13, 2017 | Oct 13, 2017 | none ahead |
| Johnson & Johnson | 11 open or running | phase 2since Aug 25, 2025 | Aug 25, 2025 | Apr 12, 2028phase 2 · NCT07149857 |
| neukio-biotherapeutics-shanghai-co-ltd | 11 open or running | early phase 1since Aug 19, 2025 | Aug 19, 2025 | Jan 14, 2027early phase 1 · NCT07144462 |
| precision-biosciences-inc | 10 open or running | phase 2since Jul 19, 2019 | Jul 19, 2019 | none ahead |
| seah-lim-m-d | 10 open or running | phase 2since Aug 29, 2012 | Aug 29, 2012 | none ahead |
| shanghai-ming-ju-biotechnology-co-ltd | 11 open or running | phase 1since Feb 5, 2023 | Feb 5, 2023 | none ahead |
| shanghai-unicar-therapy-bio-medicine-technology-co-ltd | 11 open or running | phase 1since Mar 28, 2021 | Mar 28, 2021 | none ahead |
| TCRCure Biopharma | 11 open or running | early phase 1since Nov 17, 2025 | Nov 17, 2025 | Nov 30, 2027early phase 1 · NCT07246304 |
Also a collaborator on its studies: Natera.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Oct 16, 2007.
- Feb 5, 2023shanghai-ming-ju-biotechnology-co-ltd's first study: phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNew to shanghai-ming-ju-biotechnology-co-ltdshanghai-ming-ju-biotechnology-co-ltd · NCT05727683 · 33 planned · China
- Jun 26, 2024Phase 2 study in Lymphoma, Large B-Cell, DiffuseAllogene Therapeutics · NCT06500273 · 250 planned · United States, Australia, Canada and more
- Jul 30, 2024Shanghai First Song Biotechnology's first studies: 2 early phase 1 studiesNew to Shanghai First Song BiotechnologyShanghai First Song Biotechnology · NCT06532643, NCT06532630
- Feb 7, 2025Bristol-Myers Squibb's first study: phase 1 study in Autoimmune DiseasesNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT07115745 · 125 planned · United States, Australia, Brazil and more
- Jul 8, 2025Phase 1 study in Lupus Erythematosus, SystemicAllogene Therapeutics · NCT07085104 · 66 planned · United States, Canada
- Jul 22, 2025Hangzhou Huasai Biomedicine's first study: phase 1 study in Advanced Non-Small Cell Lung CancerNew to Hangzhou Huasai BiomedicineHangzhou Huasai Biomedicine · NCT07105176 · 12 planned · China
- Aug 19, 2025neukio-biotherapeutics-shanghai-co-ltd's first study: early phase 1 study in AutoimmuneNew to neukio-biotherapeutics-shanghai-co-ltdneukio-biotherapeutics-shanghai-co-ltd · NCT07144462 · 8 planned · China
- Aug 25, 2025Johnson & Johnson's first study: phase 2 study in Multiple MyelomaNew to Johnson & JohnsonJohnson & Johnson · NCT07149857 · 60 planned · United States, Australia, Spain
- Nov 17, 2025TCRCure Biopharma's first study: early phase 1 study in Small Cell Lung CarcinomaNew to TCRCure BiopharmaTCRCure Biopharma · NCT07246304 · 24 planned · China
- Mar 14, 2026Beijing Biotech's first studies: 2 phase 1 studiesNew to Beijing BiotechBeijing Biotech · NCT07480941, NCT07492628
- Apr 5, 20264 phase 2 studiesPhase 2 reachedBeijing Biotech · NCT07523542, NCT07523529, NCT07551362 and 1 more
- Apr 18, 2026Phase 1 study in GliomaBeijing Biotech · NCT07551336 · 36 planned · China
- May 14, 20262 phase 2 studiesBeijing Biotech · NCT07598955, NCT07617805
- Sep 15, 2026Phase 1 study in Advanced NSCLCHangzhou Huasai Biomedicine · NCT07830342 · 24 planned · China
Ahead
- Jan 14, 2027Primary completion: early phase 1 study in Autoimmuneneukio-biotherapeutics-shanghai-co-ltd · NCT07144462
- Feb 18, 2027Primary completion: phase 1 study in GlioblastomaBeijing Biotech · NCT07480941
- Mar 14, 2027Primary completion: phase 2 study in RecurrenceBeijing Biotech · NCT07617805
- Mar 14, 2027Primary completion: phase 2 study in Stomach NeoplasmsBeijing Biotech · NCT07551362
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07830342Advanced NSCLC · China | 1 | Recruiting | Hangzhou Huasai Biomedicine | Oct 2028 | 24 |
| NCT07617805Recurrence · China | 2 | Recruiting | Beijing Biotech | Mar 14, 2027 | 42 |
| NCT07598955Thymoma · China | 2 | Recruiting | Beijing Biotech | Jun 14, 2027 | 36 |
| NCT07551362Stomach Neoplasms · China | 2 | Recruiting | Beijing Biotech | Mar 14, 2027 | 36 |
| NCT07551349Clear-cell metastatic renal cell carcinoma · China | 2 | Recruiting | Beijing Biotech | Apr 14, 2027 | 36 |
| NCT07551336Glioma · China | 1 | Recruiting | Beijing Biotech | Apr 14, 2027 | 36 |
| NCT07523542Lupus Erythematosus, Systemic · China | 2 | Recruiting | Beijing Biotech | Mar 14, 2027 | 24 |
| NCT07523529Neoplasm Metastasis · China | 2 | Recruiting | Beijing Biotech | Apr 14, 2027 | 72 |
| NCT07492628Urinary Bladder Neoplasms · China | 1 | Recruiting | Beijing Biotech | Jun 14, 2027 | 42 |
| NCT07480941Glioblastoma · China | 1 | Recruiting | Beijing Biotech | Feb 18, 2027 | 36 |
| NCT07246304Small Cell Lung Carcinoma · China | Early 1 | Recruiting | TCRCure Biopharma | Nov 30, 2027 | 24 |
| NCT07149857Multiple Myeloma · United States, Australia, Spain | 2 | Recruiting | Johnson & Johnson | Apr 12, 2028 | 60 |
| NCT07144462Autoimmune · China | Early 1 | Recruiting | neukio-biotherapeutics-shanghai-co-ltd | Jan 14, 2027 | 8 |
| NCT07105176Advanced Non-Small Cell Lung Cancer · China | 1 | Recruiting | Hangzhou Huasai Biomedicine | Aug 30, 2027 | 12 |
| NCT07085104Lupus Erythematosus, Systemic · United States, Canada | 1 | Recruiting | Allogene Therapeutics | Feb 2028 | 66 |
| NCT07115745Autoimmune Diseases · United States, Australia, Brazil and more | 1 | Recruiting | Bristol-Myers Squibb | Mar 15, 2029 | 125 |
| NCT06532643Lymphoma · China | Early 1 | UNKNOWN | Shanghai First Song Biotechnology | Sep 1, 2025 | 9 |
| NCT06532630B-Cell Malignancy · China | Early 1 | Recruiting | Shanghai First Song Biotechnology | Sep 1, 2025 | 9 |
| NCT06500273Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada and more | 2 | Recruiting | Allogene Therapeutics | Dec 2027 | 250 |
| NCT05727683Precursor Cell Lymphoblastic Leukemia-Lymphoma · China | 1 | Recruiting | shanghai-ming-ju-biotechnology-co-ltd | Oct 31, 2023 | 33 |
| NCT05714345Recurrence · United States, Belgium | 2 | Terminated | Allogene Therapeutics | Feb 20, 2024 | 2 |
| NCT04825496Recurrence · China | 1 | Recruiting | shanghai-unicar-therapy-bio-medicine-technology-co-ltd | Dec 31, 2023 | 18 |
| NCT04735471Lymphoma, Follicular · United States | 1 | Terminated | adicet-therapeutics | Feb 3, 2025 | 34 |
| NCT04637763Lymphoma, Non-Hodgkin · United States, Australia, Israel | 1 | Active, not recruiting | Caribou Biosciences | Sep 11, 2025 | 72 |
| NCT04030195Lymphoma, Non-Hodgkin · United States | 2 | Completed | precision-biosciences-inc | Jun 24, 2021 | 18 |
| NCT03318861Multiple Myeloma · United States | 1 | Terminated | Gilead Sciences | Dec 17, 2018 | 17 |
| NCT02876978Lung Squamous Cell Carcinoma · China | 1 | UNKNOWN | carsgen-therapeutics-co-ltd | Oct 2017 | 20 |
| NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela | 2 | Completed | Hoffmann-La Roche | Dec 2014 | 34 |
| NCT01679041Multiple Sclerosis · United States | 2 | Terminated | seah-lim-m-d | Nov 2013 | 1 |
| NCT01292603Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Brazil and more | 1 | Completed | Hoffmann-La Roche | May 7, 2014 | 240 |
| NCT01283386Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation | 4 | Terminated | Hoffmann-La Roche | Mar 16, 2016 | 26 |
| NCT01271010Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation | 4 | Terminated | Hoffmann-La Roche | May 4, 2016 | 89 |
| NCT01263704Leukemia, Lymphocytic, Chronic, B-Cell · Israel | 2 | Completed | Hoffmann-La Roche | Apr 3, 2017 | 42 |
| NCT00625430Prostatic Neoplasms · Australia | 1 | UNKNOWN | biotech-equity-partners-pty-ltd | Dec 2012 | 18 |
| NCT00545714Leukemia, Lymphocytic, Chronic, B-Cell · Spain | 2 | Completed | Hoffmann-La Roche | May 20, 2016 | 86 |
How it is read
Names in the registry
- “Fludarabine”, 40 entries
- “Cyclophosphamide,Fludarabine”, 4 entries
- “TC-D101 CAR-T”, 1 entry
- “CD19-targeted Chimeric Antigen Receptor (CAR) T Cells”, 1 entry
- “fludarabine, rituximab, pixantrone”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 7 studies
- Multiple Myeloma, 4 studies
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 3 studies
- Lymphoma, Non-Hodgkin, 3 studies
- Glioblastoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.